FPRX Five Prime Therapeutics, Inc. Stock Quote

FPRX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.68	Insider Own	0.80%	Shs Outstand	46.32M	Perf Week	-19.43%
Market Cap	594.54M	Forward P/E	-	EPS next Y	-2.08	Insider Trans	-95.23%	Shs Float	36.10M	Perf Month	-26.85%
Income	-94.80M	PEG	-	EPS next Q	-0.53	Inst Own	47.30%	Short Float	3.17%	Perf Quarter	143.91%
Sales	17.10M	P/S	34.77	EPS this Y	5.10%	Inst Trans	-23.80%	Short Ratio	0.45	Perf Half Y	101.27%
Book/sh	2.68	P/B	5.31	EPS next Y	9.60%	ROA	-49.10%	Target Price	27.14	Perf Year	176.12%
Cash/sh	2.66	P/C	5.34	EPS next 5Y	-	ROE	-75.80%	52W Range	1.75 - 24.70	Perf YTD	-16.40%
Dividend	-	P/FCF	-	EPS past 5Y	-16.90%	ROI	-94.30%	52W High	-42.43%	Beta	4.45
Dividend %	-	Quick Ratio	5.30	Sales past 5Y	-5.00%	Gross Margin	-	52W Low	712.57%	ATR	1.50
Employees	87	Current Ratio	5.30	Sales Q/Q	-33.30%	Oper. Margin	-	RSI (14)	37.71	Volatility	11.42% 8.20%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	27.80%	Profit Margin	-	Rel Volume	0.70	Prev Close	15.96
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 03 AMC	Payout	-	Avg Volume	2.53M	Price	14.22
Recom	1.60	SMA20	-20.68%	SMA50	-14.16%	SMA200	85.11%	Volume	1,759,927	Change	-10.90%

Nov-11-20

Upgrade

Wells Fargo

Equal Weight → Overweight

$34

Nov-11-20

Upgrade

ROTH Capital

Neutral → Buy

$9 → $30

Nov-11-20

Upgrade

JP Morgan

Underweight → Neutral

$14

Sep-22-20

Upgrade

Guggenheim

Neutral → Buy

$11

Jun-22-20

Upgrade

Wedbush

Neutral → Outperform

$5 → $9

Feb-28-20

Downgrade

JP Morgan

Neutral → Underweight

Feb-18-20

Downgrade

Wedbush

Outperform → Neutral

Nov-20-19

Resumed

Guggenheim

Neutral

Oct-01-19

Downgrade

Guggenheim

Buy → Neutral

Jun-03-19

Downgrade

Wells Fargo

Outperform → Market Perform

May-29-19

Initiated

ROTH Capital

Neutral

$10

Apr-12-19

Resumed

Guggenheim

Buy

$24

Sep-13-18

Resumed

Leerink Partners

Outperform

$24

Jun-28-18

Initiated

Raymond James

Mkt Perform

Jun-15-18

Initiated

JP Morgan

Neutral

$19

May-18-18

Initiated

Wedbush

Neutral

Nov-06-17

Reiterated

RBC Capital Mkts

Outperform

$41 → $50

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$41

Mar-02-17

Initiated

Instinet

Buy

$94

Oct-25-16

Initiated

Citigroup

Buy

Jan-15-21 06:55AM	Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers Business Wire -10.90%
Dec-21-20 01:20AM	We're Hopeful That Five Prime Therapeutics (NASDAQ:FPRX) Will Use Its Cash Wisely Simply Wall St.
Dec-17-20 11:18PM	Is FPRX A Good Stock To Buy Now? Insider Monkey
Dec-09-20 05:00PM	Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Virtual Annual Symposium Business Wire -12.42%
Dec-08-20 10:00AM	Why Five Prime Therapeutics Stock Gained 312% in November Motley Fool
Dec-07-20 08:29AM	These Were the 5 Best Cancer Stocks Of 2020 Motley Fool
Dec-05-20 04:00PM	Have $1,000? Here Are 3 Top Healthcare Stocks to Buy in December Motley Fool
Nov-17-20 05:00PM	Five Prime Announces Closing of Upsized Public Offering of Common Stock Business Wire
10:00AM	2 Biotech Stocks That Could Double Your Money Motley Fool
Nov-13-20 07:40AM	The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga
Nov-12-20 10:00PM	Five Prime Announces Pricing of Upsized Public Offering of Common Stock Business Wire +24.61%
04:16PM	Small Biotech Five Prime Launches For A Second Day Running Here's Why Investor's Business Daily
08:34AM	Are Options Traders Betting on a Big Move in Five Prime (FPRX) Stock? Zacks
07:44AM	The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga
Nov-11-20 05:45PM	Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157 Business Wire +237.08%
04:19PM	Why This Tiny Biotech Stock More Than Tripled In Bullish Volume Investor's Business Daily
04:01PM	Five Prime Announces Proposed Public Offering of Common Stock Business Wire
02:00PM	Is Five Prime Stock a Buy Right Now? This Is What You Need To Know TipRanks
01:24PM	You've Probably Never Heard of the Stock Market's Biggest Winner Wednesday Motley Fool
12:22PM	Small-Cap Biotech Surges Almost 350% on Cancer-Drug Trial Data Bloomberg
11:11AM	Five Prime Therapeutics Rises After Positive Cancer Drug Trial TheStreet.com
08:30AM	Why Five Prime Therapeutics Stock Is on Fire Today Motley Fool
07:38AM	The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga
07:36AM	Five Prime's stock rockets over 350% after positive trial results from cancer treatment, analyst upgrade MarketWatch
Nov-10-20 07:00PM	Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric or Gastroesophageal Junction Cancer GlobeNewswire
04:12PM	Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer Business Wire
Nov-06-20 06:47AM	Here's What Analysts Are Forecasting For Five Prime Therapeutics, Inc. (NASDAQ:FPRX) After Its Third-Quarter Results Simply Wall St.
Nov-03-20 05:15PM	Five Prime Therapeutics (FPRX) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:21PM	Recap: Five Prime Therapeutics Q3 Earnings Benzinga
04:05PM	Five Prime Therapeutics Reports Third Quarter 2020 Results Business Wire
02:45PM	Five Prime Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-20 06:30PM	Five Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting Business Wire
Oct-28-20 12:32PM	Will Five Prime Therapeutics (FPRX) Report Negative Q3 Earnings? What You Should Know Zacks -11.59%
Oct-27-20 10:29PM	Five Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference Call Business Wire
Oct-13-20 02:47PM	Hedge Funds Are Coming Back To Five Prime Therapeutics Inc (FPRX) Insider Monkey
Oct-12-20 08:48AM	Five Prime (FPRX) Looks Good: Stock Adds 5.1% in Session Zacks +13.20%
Oct-09-20 09:50AM	Reflecting on Five Prime Therapeutics' (NASDAQ:FPRX) Share Price Returns Over The Last Three Years Simply Wall St. +5.08%
Sep-22-20 09:36AM	Benzinga's Top Upgrades, Downgrades For September 22, 2020 Benzinga
Sep-09-20 06:30PM	Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference Business Wire
Aug-13-20 03:30PM	Wedbush: 3 Healthcare Stocks Under $10 With Massive Upside Ahead TipRanks
Aug-10-20 12:56PM	Do Institutions Own Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Shares? Simply Wall St. -8.01%
12:55PM	What Type Of Shareholders Own The Most Number of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Shares? Simply Wall St.
Aug-06-20 08:30PM	Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM	Five Prime Therapeutics Reports Second Quarter 2020 Results Business Wire
Jul-30-20 12:33PM	Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks +6.30%
Jul-29-20 07:00PM	Five Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire
06:30PM	Five Prime Therapeutics Announces Timing of Its Second Quarter 2020 Results Conference Call Business Wire
12:33PM	Will Five Prime Therapeutics (FPRX) Report Negative Q2 Earnings? What You Should Know Zacks
Jun-26-20 09:17AM	Is Five Prime Therapeutics Inc (FPRX) Going to Burn These Hedge Funds? Insider Monkey
Jun-22-20 10:48AM	Why Five Prime's Stock Is Trading Higher Today Benzinga +45.39%
Jun-11-20 07:53AM	Edited Transcript of FPRX earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents +7.04%
May-15-20 09:37AM	Is Five Prime Therapeutics (FPRX) Stock a Solid Choice Right Now? Zacks
May-10-20 09:55AM	Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
May-07-20 04:05PM	Five Prime Therapeutics Reports First Quarter 2020 Results Business Wire +11.14%
Apr-30-20 04:05PM	Five Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference Call Business Wire
Apr-22-20 04:05PM	Five Prime Therapeutics Changes 2020 Annual Meeting to Virtual Format Business Wire
Apr-14-20 09:00AM	Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer Business Wire +7.35%
Apr-09-20 07:35AM	Here's Why Five Prime Therapeutics (NASDAQ:FPRX) Must Use Its Cash Wisely Simply Wall St. +10.20%
Mar-20-20 03:32AM	Edited Transcript of FPRX earnings conference call or presentation 27-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-13-20 09:25AM	Five Prime Therapeutics Announces Publication of the Phase 1 Bemarituzumab Study in the Journal of Clinical Oncology Business Wire
Feb-27-20 05:45PM	Five Prime Therapeutics (FPRX) Reports Q4 Loss, Misses Revenue Estimates Zacks -10.56%
Feb-25-20 04:22PM	Five Prime Therapeutics to Present at Upcoming Healthcare Conference Business Wire -7.24%
Feb-20-20 12:31PM	Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-19-20 09:25AM	Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs Business Wire +18.33%
Feb-18-20 09:25AM	Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic Cancer Business Wire
Feb-13-20 04:05PM	Five Prime Therapeutics Announces Timing of Its Fourth Quarter and Full Year 2019 Results Conference Call Business Wire -8.11%
Jan-10-20 09:28AM	If You Had Bought Five Prime Therapeutics (NASDAQ:FPRX) Stock Three Years Ago, You'd Be Sitting On A 89% Loss, Today Simply Wall St. -6.00%
Dec-30-19 01:05PM	Five Prime Therapeutics to Participate in the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-27-19 02:26PM	Longtime biotech exec walks away from board to concentrate on startup American City Business Journals
Dec-26-19 04:05PM	Five Prime Therapeutics Announces Resignation of Dr. Lewis T. "Rusty" Williams From Board of Directors Business Wire
Dec-20-19 01:54PM	Head of big South San Francisco biotech thriving in first CEO role American City Business Journals
Dec-16-19 06:17PM	Edited Transcript of FPRX earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents -5.80%
Dec-10-19 11:14AM	Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy ? Insider Monkey +5.14%
Nov-09-19 07:00AM	Five Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting Business Wire
Nov-08-19 01:02PM	Insiders Roundup: Crocs, OPKO Health GuruFocus.com
Nov-06-19 06:45PM	Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM	Five Prime Therapeutics Reports Third Quarter 2019 Results Business Wire
Oct-30-19 10:33AM	Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Oct-24-19 04:01PM	Five Prime Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call Business Wire
Oct-11-19 04:04PM	Insiders Roundup: Facebook, American Defense Systems GuruFocus.com
08:14AM	The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga
Oct-10-19 09:57PM	South San Francisco biotech to cut another 70 jobs, may sublease space American City Business Journals
04:01PM	Five Prime Announces Restructuring Business Wire
Oct-02-19 07:30AM	Looking for 1,600% Returns? Biotech Has No Shortage of Analyst Optimism Bloomberg +5.15%
Sep-30-19 03:01AM	Five Prime Therapeutics Presents Updated Data From the Phase 1a/1b Trial of FPA150 at the European Society for Medical Oncology 2019 Congress Business Wire -9.36%
Sep-20-19 09:59AM	Peninsula biotech CEO resigns in latest corner office switch American City Business Journals
Sep-19-19 04:05PM	Five Prime Therapeutics Announces Management Transition Business Wire
12:18PM	What Kind Of Shareholder Owns Most Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Stock? Simply Wall St.
Aug-22-19 07:45PM	Five Prime Therapeutics to Present at Upcoming Healthcare Conference Business Wire
Aug-15-19 10:16PM	Edited Transcript of FPRX earnings conference call or presentation 7-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-07-19 06:25PM	Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM	Five Prime Therapeutics Reports Second Quarter 2019 Results Business Wire
Aug-01-19 03:06PM	Cancer-fighting Peninsula company postpones $92 million IPO American City Business Journals
Jun-25-19 11:56AM	Estimating The Fair Value Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Simply Wall St.
Jun-24-19 04:05PM	Five Prime Therapeutics Appoints Lori Lyons-Williams to its Board of Directors Business Wire
01:28PM	Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy? Insider Monkey
Jun-18-19 08:50AM	Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session Zacks
Jun-09-19 03:05PM	Five Prime Therapeutics Announces the Departure of Dr. Sheila Gujrathi From its Board of Directors Business Wire
03:00PM	Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences Business Wire
Jun-01-19 09:01AM	Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at the 2019 ASCO Annual Meeting Business Wire

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sarena Francis Willard	Chief Strategy Officer	Dec 11	Option Exercise	0.00	22,000	0	138,010	Dec 15 12:19 PM
Smith David V	Executive Vice President & CFO	Dec 11	Option Exercise	0.00	22,000	0	89,561	Dec 15 12:09 PM
Collins Helen Louise	EVP and Chief Medical Officer	Dec 11	Option Exercise	0.00	22,000	0	97,117	Dec 15 12:00 PM
RINGO WILLIAM R	Director	Nov 11	Option Exercise	2.41	78,959	190,369	62,959	Nov 13 12:17 PM
Sarena Francis Willard	Chief Strategy Officer	Nov 11	Option Exercise	0.00	22,000	0	127,011	Nov 13 12:38 PM
Smith David V	Executive Vice President & CFO	Nov 11	Option Exercise	0.00	22,000	0	85,389	Nov 13 12:29 PM
Collins Helen Louise	EVP and Chief Medical Officer	Nov 11	Option Exercise	0.00	22,000	0	86,156	Nov 13 12:25 PM
BVF PARTNERS L P/IL	See Explanaton of Responses	Nov 11	Sale	20.19	7,393,340	149,247,137	81,263	Nov 13 05:29 PM
RINGO WILLIAM R	Director	Nov 11	Sale	22.50	78,959	1,776,578	10,000	Nov 13 12:17 PM
BVF PARTNERS L P/IL	10% Owner	Nov 06	Buy	4.98	30,000	149,520	4,611,909	Nov 06 06:30 PM
BVF PARTNERS L P/IL	10% Owner	Nov 04	Buy	4.88	416,562	2,034,572	4,594,679	Nov 06 06:30 PM
BVF PARTNERS L P/IL	10% Owner	Oct 06	Buy	5.04	345,241	1,738,288	4,336,875	Oct 08 05:27 PM
BVF PARTNERS L P/IL	10% Owner	Sep 22	Buy	3.80	32	122	541,116	Sep 24 07:49 PM
BVF PARTNERS L P/IL	10% Owner	May 14	Buy	4.10	293,587	1,203,707	4,179,093	May 18 08:02 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience